Literature DB >> 31832725

Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD.

Corinne E Metzger1, Elizabeth A Swallow1, Matthew R Allen2,3,4,5,6.   

Abstract

Chronic kidney disease (CKD) leads to significant bone loss primarily through the development of cortical porosity. In both patients and animal models of CKD, sustained elevations in serum parathyroid hormone (PTH) are associated with cortical porosity. In this study, we aimed to track the progression of cortical porosity and increased PTH utilizing the adenine-induced CKD model. Young female mice (8 weeks) were given 0.2% adenine to induce CKD. Tissues were collected from groups of adenine and age-matched control mice after 2, 6, and 10 weeks. Serum blood urea nitrogen was elevated at all time points in adenine mice, but serum PTH was only statistically elevated at the 10-week time point. Cortical porosity was sevenfold higher in 6-week adenine mice compared to age-matched controls and 14-fold higher in 10-week adenine mice vs. controls. Additionally, osteocyte receptor activator of nuclear factor κB ligand (RANKL) was elevated in adenine-fed mice, while annexin V, an early marker of cellular apoptosis, was mildly decreased in osteocytes in adenine-fed mice. Based on these results, we hypothesize high serum PTH signals to osteocytes prolonging their lifespan resulting in sustained RANKL which drives osteoclastic bone resorption in the cortex. In conclusion, our data show time-dependent elevations in serum PTH and cortical porosity in adenine-induced CKD mice and demonstrate changes in osteocyte RANKL and apoptosis which may contribute to the development of cortical pores.

Entities:  

Keywords:  Adenine; Chronic kidney disease; Cortical porosity; Parathyroid hormone

Mesh:

Substances:

Year:  2019        PMID: 31832725      PMCID: PMC7422916          DOI: 10.1007/s00223-019-00642-w

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  39 in total

1.  Chronic kidney disease induced by adenine: a suitable model of growth retardation in uremia.

Authors:  Débora Claramunt; Helena Gil-Peña; Rocío Fuente; Enrique García-López; Vanessa Loredo; Olaya Hernández-Frías; Flor A Ordoñez; Julián Rodríguez-Suárez; Fernando Santos
Journal:  Am J Physiol Renal Physiol       Date:  2015-05-13

2.  Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease.

Authors:  S Anand Narayanan; Corinne E Metzger; Susan A Bloomfield; David C Zawieja
Journal:  FASEB J       Date:  2018-03-29       Impact factor: 5.191

Review 3.  For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases.

Authors:  Stavros C Manolagas; A Michael Parfitt
Journal:  Bone       Date:  2012-09-23       Impact factor: 4.398

4.  Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

Authors:  M Jadoul; J M Albert; T Akiba; T Akizawa; L Arab; J L Bragg-Gresham; N Mason; K-G Prutz; E W Young; R L Pisoni
Journal:  Kidney Int       Date:  2006-08-23       Impact factor: 10.612

5.  Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.

Authors:  Robert S Weinstein; Robert L Jilka; Maria Almeida; Paula K Roberson; Stavros C Manolagas
Journal:  Endocrinology       Date:  2010-04-21       Impact factor: 4.736

6.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

7.  The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.

Authors:  Charles Henley; James Davis; Gerald Miller; Edward Shatzen; Russ Cattley; Xiaodong Li; David Martin; Wei Yao; Nancy Lane; Victoria Shalhoub
Journal:  Eur J Pharmacol       Date:  2009-05-24       Impact factor: 4.432

8.  Endochondral bone formation is involved in media calcification in rats and in men.

Authors:  E Neven; S Dauwe; M E De Broe; P C D'Haese; V Persy
Journal:  Kidney Int       Date:  2007-05-30       Impact factor: 10.612

9.  Matrix-embedded cells control osteoclast formation.

Authors:  Jinhu Xiong; Melda Onal; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

10.  Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models.

Authors:  Guaraciaba O Ferrari; Juliana C Ferreira; Raquel T Cavallari; Katia R Neves; Luciene M dos Reis; Wagner V Dominguez; Elizabeth C Oliveira; Fabiana G Graciolli; Jutta Passlick-Deetjen; Vanda Jorgetti; Rosa M A Moysés
Journal:  BMC Nephrol       Date:  2014-05-03       Impact factor: 2.388

View more
  9 in total

1.  The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.

Authors:  Samantha P Tippen; Corinne E Metzger; Elizabeth A Swallow; Spencer A Sacks; Joseph M Wallace; Matthew R Allen
Journal:  Bone       Date:  2021-10-05       Impact factor: 4.398

Review 2.  Cortical bone development, maintenance and porosity: genetic alterations in humans and mice influencing chondrocytes, osteoclasts, osteoblasts and osteocytes.

Authors:  Tsuyoshi Isojima; Natalie A Sims
Journal:  Cell Mol Life Sci       Date:  2021-07-01       Impact factor: 9.261

3.  Measuring Bone Volume at Multiple Densities by Micro-computed Tomography.

Authors:  Emma C Walker; Narelle E McGregor; Audrey S M Chan; Natalie A Sims
Journal:  Bio Protoc       Date:  2021-01-05

4.  Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels.

Authors:  Corinne E Metzger; Elizabeth A Swallow; Alexander J Stacy; Matthew R Allen
Journal:  Bone       Date:  2021-04-17       Impact factor: 4.626

5.  The Effect of Single Versus Group μCT on the Detection of Trabecular and Cortical Disease Phenotypes in Mouse Bones.

Authors:  Rachel Kohler; Carli A Tastad; Alexander J Stacy; Elizabeth A Swallow; Corinne E Metzger; Matthew R Allen; Joseph M Wallace
Journal:  JBMR Plus       Date:  2021-03-05

6.  CKD Stages, Bone Metabolism Markers, and Cortical Porosity Index: Associations and Mediation Effects Analysis.

Authors:  Yan Xiong; Tongxiang He; Yanan Wang; Weiyin Vivian Liu; Shuang Hu; Yao Zhang; Donglin Wen; Bowen Hou; Yitong Li; Peisen Zhang; Jianyi Liu; Fan He; Xiaoming Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-05       Impact factor: 5.555

7.  Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.

Authors:  Elizabeth A Swallow; Corinne E Metzger; Neal X Chen; Joseph M Wallace; Samantha P Tippen; Rachel Kohler; Sharon M Moe; Matthew R Allen
Journal:  Bone Rep       Date:  2022-02-07

8.  Cortical porosity occurs at varying degrees throughout the skeleton in rats with chronic kidney disease.

Authors:  Corinne E Metzger; Christopher L Newman; Samantha P Tippen; Natalie T Golemme; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Bone Rep       Date:  2022-08-17

9.  Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy.

Authors:  Shun-Neng Hsu; Louise A Stephen; Scott Dillon; Elspeth Milne; Behzad Javaheri; Andrew A Pitsillides; Amanda Novak; Jose Luis Millán; Vicky E MacRae; Katherine A Staines; Colin Farquharson
Journal:  J Endocrinol       Date:  2022-08-12       Impact factor: 4.669

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.